Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer
Objective.The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer. Methods.Thirty patients with stage III/IV epithelial ovarian cancer underwent cyto...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 1998-02, Vol.68 (2), p.166-168 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 168 |
|---|---|
| container_issue | 2 |
| container_start_page | 166 |
| container_title | Gynecologic oncology |
| container_volume | 68 |
| creator | Brown, John V. Rettenmaier, Mark A. Dillman, Robert A. Birk, Connie L. Culkin, Kathleen Micha, John Paul |
| description | Objective.The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer.
Methods.Thirty patients with stage III/IV epithelial ovarian cancer underwent cytoreductive surgery. The first 10 patients received adjuvant paclitaxel 150 mg/m2via 3-h infusion on day 1 and carboplatin 5 times area under the curve on day 2 (group 1) every 28 days. The paclitaxel dose was escalated to 175 mg/m2for the next 20 patients (group 2). χ2and Kaplan–Meier procedures were used for statistical analysis.
Results.Nine of 51 cycles in group 1 (17.6%) and 19 of 116 cycles (16.4%) in group 2 were associated with grade 4 neutropenia (P= 0.96), but only 2 of the 161 total cycles (0.01%) had fever and neutropenia. One patient in group 1 experienced grade 3 thrombocytopenia. Two patients in the entire group (7.4%) required colony-stimulating factors. One patient in group 2 (3.7%) had grade 3 neurotoxicity. With a median follow-up of 29 months for the entire group, 5 of 8 patients (62.5%) in group 1 and 14 of 19 patients (73.7%) in group 2 are alive. Median progression-free survival for group 1 and 2 is 13 and 14 months, respectively. Median overall survival has not been reached.
Conclusions.Paclitaxel via 3-h infusion and carboplatin is an effective outpatient treatment for epithelial ovarian cancer that can be safely administered on schedule in the majority of patients. |
| doi_str_mv | 10.1006/gyno.1997.4916 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1006_gyno_1997_4916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825897949167</els_id><sourcerecordid>9514805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-22f88dfd0a01cd047d2cb22ae07179b52a7345788127738af6a63932f79107f23</originalsourceid><addsrcrecordid>eNp1kEFr3DAQhUVpSbZJr70FdOjVm5FsWdKxLJvGENhAN2czK0uJitc2knZpyJ-PzC655TTDvPeGmY-QnwyWDKC-fX4dxiXTWi4rzeovZMFAi6JWQn8lCwANheJCXZLvMf4DgBIYvyAXWrBKgViQt-1LsLa4Hw-BPqLpfcL_tqfN4A7RjwPFoaMrDLtx6jH5gTYxj-jaOWuSP1q6OaQpC3ZIdBsspv3cuTHQvwmfLW2ahq4nn15s77GnmyMGn_MrHIwN1-Sbwz7aH-d6RZ7u1tvVffGw-dOsfj8UpqrLVHDulOpcBwjMdFDJjpsd52hBMql3gqMsKyGVYlzKUqGrsS51yZ3UDKTj5RVZnvaaMMYYrGun4PcYXlsG7QyxnSG2M8R2hpgDN6fAdNjtbfdhP1PL-q-zjtFg70J-x8cPG2dKgFDZpk42m587ehvaaDIpYzsfMr62G_1nF7wDYCqN6A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Brown, John V. ; Rettenmaier, Mark A. ; Dillman, Robert A. ; Birk, Connie L. ; Culkin, Kathleen ; Micha, John Paul</creator><creatorcontrib>Brown, John V. ; Rettenmaier, Mark A. ; Dillman, Robert A. ; Birk, Connie L. ; Culkin, Kathleen ; Micha, John Paul</creatorcontrib><description>Objective.The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer.
Methods.Thirty patients with stage III/IV epithelial ovarian cancer underwent cytoreductive surgery. The first 10 patients received adjuvant paclitaxel 150 mg/m2via 3-h infusion on day 1 and carboplatin 5 times area under the curve on day 2 (group 1) every 28 days. The paclitaxel dose was escalated to 175 mg/m2for the next 20 patients (group 2). χ2and Kaplan–Meier procedures were used for statistical analysis.
Results.Nine of 51 cycles in group 1 (17.6%) and 19 of 116 cycles (16.4%) in group 2 were associated with grade 4 neutropenia (P= 0.96), but only 2 of the 161 total cycles (0.01%) had fever and neutropenia. One patient in group 1 experienced grade 3 thrombocytopenia. Two patients in the entire group (7.4%) required colony-stimulating factors. One patient in group 2 (3.7%) had grade 3 neurotoxicity. With a median follow-up of 29 months for the entire group, 5 of 8 patients (62.5%) in group 1 and 14 of 19 patients (73.7%) in group 2 are alive. Median progression-free survival for group 1 and 2 is 13 and 14 months, respectively. Median overall survival has not been reached.
Conclusions.Paclitaxel via 3-h infusion and carboplatin is an effective outpatient treatment for epithelial ovarian cancer that can be safely administered on schedule in the majority of patients.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1006/gyno.1997.4916</identifier><identifier>PMID: 9514805</identifier><identifier>CODEN: GYNOA3</identifier><language>eng</language><publisher>San Diego, CA: Elsevier Inc</publisher><subject>Adult ; Aged ; Ambulatory Care ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carboplatin - administration & dosage ; Carcinoma - drug therapy ; Carcinoma - pathology ; Chemotherapy ; Drug Administration Schedule ; Female ; Humans ; Infusions, Intravenous ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Paclitaxel - administration & dosage ; Pharmacology. Drug treatments ; Treatment Outcome</subject><ispartof>Gynecologic oncology, 1998-02, Vol.68 (2), p.166-168</ispartof><rights>1998 Academic Press</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-22f88dfd0a01cd047d2cb22ae07179b52a7345788127738af6a63932f79107f23</citedby><cites>FETCH-LOGICAL-c463t-22f88dfd0a01cd047d2cb22ae07179b52a7345788127738af6a63932f79107f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825897949167$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2185058$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9514805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brown, John V.</creatorcontrib><creatorcontrib>Rettenmaier, Mark A.</creatorcontrib><creatorcontrib>Dillman, Robert A.</creatorcontrib><creatorcontrib>Birk, Connie L.</creatorcontrib><creatorcontrib>Culkin, Kathleen</creatorcontrib><creatorcontrib>Micha, John Paul</creatorcontrib><title>Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Objective.The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer.
Methods.Thirty patients with stage III/IV epithelial ovarian cancer underwent cytoreductive surgery. The first 10 patients received adjuvant paclitaxel 150 mg/m2via 3-h infusion on day 1 and carboplatin 5 times area under the curve on day 2 (group 1) every 28 days. The paclitaxel dose was escalated to 175 mg/m2for the next 20 patients (group 2). χ2and Kaplan–Meier procedures were used for statistical analysis.
Results.Nine of 51 cycles in group 1 (17.6%) and 19 of 116 cycles (16.4%) in group 2 were associated with grade 4 neutropenia (P= 0.96), but only 2 of the 161 total cycles (0.01%) had fever and neutropenia. One patient in group 1 experienced grade 3 thrombocytopenia. Two patients in the entire group (7.4%) required colony-stimulating factors. One patient in group 2 (3.7%) had grade 3 neurotoxicity. With a median follow-up of 29 months for the entire group, 5 of 8 patients (62.5%) in group 1 and 14 of 19 patients (73.7%) in group 2 are alive. Median progression-free survival for group 1 and 2 is 13 and 14 months, respectively. Median overall survival has not been reached.
Conclusions.Paclitaxel via 3-h infusion and carboplatin is an effective outpatient treatment for epithelial ovarian cancer that can be safely administered on schedule in the majority of patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Ambulatory Care</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - pathology</subject><subject>Chemotherapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Paclitaxel - administration & dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Treatment Outcome</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFr3DAQhUVpSbZJr70FdOjVm5FsWdKxLJvGENhAN2czK0uJitc2knZpyJ-PzC655TTDvPeGmY-QnwyWDKC-fX4dxiXTWi4rzeovZMFAi6JWQn8lCwANheJCXZLvMf4DgBIYvyAXWrBKgViQt-1LsLa4Hw-BPqLpfcL_tqfN4A7RjwPFoaMrDLtx6jH5gTYxj-jaOWuSP1q6OaQpC3ZIdBsspv3cuTHQvwmfLW2ahq4nn15s77GnmyMGn_MrHIwN1-Sbwz7aH-d6RZ7u1tvVffGw-dOsfj8UpqrLVHDulOpcBwjMdFDJjpsd52hBMql3gqMsKyGVYlzKUqGrsS51yZ3UDKTj5RVZnvaaMMYYrGun4PcYXlsG7QyxnSG2M8R2hpgDN6fAdNjtbfdhP1PL-q-zjtFg70J-x8cPG2dKgFDZpk42m587ehvaaDIpYzsfMr62G_1nF7wDYCqN6A</recordid><startdate>19980201</startdate><enddate>19980201</enddate><creator>Brown, John V.</creator><creator>Rettenmaier, Mark A.</creator><creator>Dillman, Robert A.</creator><creator>Birk, Connie L.</creator><creator>Culkin, Kathleen</creator><creator>Micha, John Paul</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19980201</creationdate><title>Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer</title><author>Brown, John V. ; Rettenmaier, Mark A. ; Dillman, Robert A. ; Birk, Connie L. ; Culkin, Kathleen ; Micha, John Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-22f88dfd0a01cd047d2cb22ae07179b52a7345788127738af6a63932f79107f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Ambulatory Care</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - pathology</topic><topic>Chemotherapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Paclitaxel - administration & dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brown, John V.</creatorcontrib><creatorcontrib>Rettenmaier, Mark A.</creatorcontrib><creatorcontrib>Dillman, Robert A.</creatorcontrib><creatorcontrib>Birk, Connie L.</creatorcontrib><creatorcontrib>Culkin, Kathleen</creatorcontrib><creatorcontrib>Micha, John Paul</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brown, John V.</au><au>Rettenmaier, Mark A.</au><au>Dillman, Robert A.</au><au>Birk, Connie L.</au><au>Culkin, Kathleen</au><au>Micha, John Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>1998-02-01</date><risdate>1998</risdate><volume>68</volume><issue>2</issue><spage>166</spage><epage>168</epage><pages>166-168</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><coden>GYNOA3</coden><abstract>Objective.The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer.
Methods.Thirty patients with stage III/IV epithelial ovarian cancer underwent cytoreductive surgery. The first 10 patients received adjuvant paclitaxel 150 mg/m2via 3-h infusion on day 1 and carboplatin 5 times area under the curve on day 2 (group 1) every 28 days. The paclitaxel dose was escalated to 175 mg/m2for the next 20 patients (group 2). χ2and Kaplan–Meier procedures were used for statistical analysis.
Results.Nine of 51 cycles in group 1 (17.6%) and 19 of 116 cycles (16.4%) in group 2 were associated with grade 4 neutropenia (P= 0.96), but only 2 of the 161 total cycles (0.01%) had fever and neutropenia. One patient in group 1 experienced grade 3 thrombocytopenia. Two patients in the entire group (7.4%) required colony-stimulating factors. One patient in group 2 (3.7%) had grade 3 neurotoxicity. With a median follow-up of 29 months for the entire group, 5 of 8 patients (62.5%) in group 1 and 14 of 19 patients (73.7%) in group 2 are alive. Median progression-free survival for group 1 and 2 is 13 and 14 months, respectively. Median overall survival has not been reached.
Conclusions.Paclitaxel via 3-h infusion and carboplatin is an effective outpatient treatment for epithelial ovarian cancer that can be safely administered on schedule in the majority of patients.</abstract><cop>San Diego, CA</cop><pub>Elsevier Inc</pub><pmid>9514805</pmid><doi>10.1006/gyno.1997.4916</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 1998-02, Vol.68 (2), p.166-168 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_crossref_primary_10_1006_gyno_1997_4916 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged Ambulatory Care Antineoplastic agents Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carboplatin - administration & dosage Carcinoma - drug therapy Carcinoma - pathology Chemotherapy Drug Administration Schedule Female Humans Infusions, Intravenous Medical sciences Middle Aged Neoplasm Staging Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Paclitaxel - administration & dosage Pharmacology. Drug treatments Treatment Outcome |
| title | Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T22%3A51%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Three-Hour%20Paclitaxel%20Infusion%20and%20Carboplatin%20Is%20an%20Effective%20Outpatient%20Treatment%20for%20Stage%20III%20Epithelial%20Ovarian%20Cancer&rft.jtitle=Gynecologic%20oncology&rft.au=Brown,%20John%20V.&rft.date=1998-02-01&rft.volume=68&rft.issue=2&rft.spage=166&rft.epage=168&rft.pages=166-168&rft.issn=0090-8258&rft.eissn=1095-6859&rft.coden=GYNOA3&rft_id=info:doi/10.1006/gyno.1997.4916&rft_dat=%3Cpubmed_cross%3E9514805%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9514805&rft_els_id=S0090825897949167&rfr_iscdi=true |